Previous Article | Next Article ![]()
Infection and Immunity, December 2000, p. 6798-6806, Vol. 68, No. 12
Department of Microbiology and Immunology,
Morehouse School of Medicine, Atlanta, Georgia
30310,1 and Pasteur Merieux
Connaught Canada, Toronto, Ontario M2R 3T4,
Canada2
Received 31 July 2000/Returned for modification 8 September
2000/Accepted 25 September 2000
The significance of delivery systems in modern vaccine design
strategies is underscored by the fact that a promising vaccine formulation may fail in vivo due to an inappropriate delivery method.
We evaluated the immunogenicity and efficacy of a candidate vaccine
comprising the major outer membrane protein (MOMP) of Chlamydia
trachomatis delivered with the lipophilic immune
response-stimulating complexes (ISCOMs) as a vehicle with adjuvant
properties, in a murine model of chlamydial genital infection.
Immunocompetent BALB/c mice were immunized intranasally (IN) or
intramuscularly (IM) with MOMP, MOMP-ISCOMs, and live or
heat-inactivated C. trachomatis serovar D. The level of
local genital mucosal Th1 response was measured by assaying for
antigen-specific Th1 cell induction and recruitment into the genital
mucosa at different times after immunization. Immunization with
MOMP-ISCOMs by the IM route induced the greatest and fastest local
genital mucosal Th1 response, first detectable 2 weeks after exposure.
Among the other routes and regimens tested, only IN immunization with
MOMP-ISCOMs induced detectable and statistically significant levels of
local genital mucosal Th1 response during the 8-week test period
(P < 0.001). In addition, when T cells from immunized
mice were adoptively transferred into syngeneic naive animals and
challenged intravaginally with Chlamydia, recipients of IM
immunization of MOMP-ISCOMs cleared their infection within 1 week and
were resistant to reinfection. Animals that received IN immunization of
MOMP-ISCOMs were partially protected, shedding fewer chlamydiae than
did control mice. Altogether, the results suggested that IM delivery of
MOMP-ISCOMs may be a suitable vaccine regimen potentially capable of
inducing protective mucosal immunity against C. trachomatis infection.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Induction of Protective Immunity against Chlamydia
trachomatis Genital Infection by a Vaccine Based on Major Outer
Membrane Protein-Lipophilic Immune Response-Stimulating
Complexes
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Morehouse School of Medicine, 720 Westview Dr., S.W., Atlanta, GA 30310. Phone: (404) 752-1596. Fax: (404) 752-1179. E-mail: igietsj{at}msm.edu.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|